Junji Hiraga

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

Junji Hiraga, Akihiro Tomita, Takumi Sugimoto et al. · Blood · 2009 · 253 citations · Full text

Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy

Akihiro Tomita, Junji Hiraga, Hitoshi Kiyoi et al. · International Journal of Hematology · 2007 · 54 citations

Hematological Malignancy, Lymphoid Neoplasia, Rituximab-containing Chemotherapy +10

Escape mechanisms from antibody therapy to lymphoma cells: Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation

Takumi Sugimoto, Akihiro Tomita, Junji Hiraga et al. · Biochemical and Biophysical Research Communications · 2009 · 49 citations · Full text

Clinical significance of nuclear non‐phosphorylated beta‐catenin in acute myeloid leukaemia and myelodysplastic syndrome

Jinglan Xu, Momoko Suzuki, Yousuke Niwa et al. · British Journal of Haematology · 2008 · 44 citations · Full text

Loss of O 6 -Methylguanine-DNA Methyltransferase Protein Expression Is a Favorable Prognostic Marker in Diffuse Large B-Cell Lymphoma

Toshihito Ohno, Junji Hiraga, Haruhiko Ohashi et al. · International Journal of Hematology · 2006 · 28 citations

Hematological Malignancy, Tumor Biology, Lymphoid Neoplasia +9